Rethinking the "pre" in pre-therapy counseling: No benefit of additional visits prior to therapy on adherence or Viremia in Ugandans initiating ARVs

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Siedner, Mark J ^a   Lankowski, Alexander ^a,b   Haberer, Jessica E ^a   Kembabazi, Annet ^b   Emenyonu, Nneka ^b   Tsai, Alexander C ^c   Muzoora, Conrad ^b   Geng, Elvin ^d   Martin, Jeffrey N ^d   Bangsberg, David R ^a,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; TREATMENT DURATION; UGANDA; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; UGANDA;

EID: 84862742404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039894     Document Type: Article

References (37)

1. (2010) UNAIDS: Report on the Global AIDS Epidemic. Available athttp://www.unaids.org/GlobalReport/default.htm. Accessed November 1, 2011.
2. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567.
3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
4. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, et al. (2009) Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 9: 290.
5. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, et al. (2009) Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 51: 135-139.
6. Losina E, Bassett IV, Giddy J, Chetty S, Regan S, et al. (2010) The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One 5: e9538.
7. McGrath N, Glynn JR, Saul J, Kranzer K, Jahn A, et al. (2010) What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public Health 10: 601.
8. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, et al. (2010) Who starts antiretroviral therapy in Durban, South Africa?. not everyone who should. AIDS 24: S37-44.
9. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34: 281-288.
10. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, et al. (2010) Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 14: 778-784.
11. Maskew M, MacPhail P, Menezes C, Rubel D, (2007) Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 97: 853-857.
12. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
13. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N, (2006) Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 43: S23-35.
14. (2009) National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children. Ministry of Health Republic of Uganda. www.idi.ac.ug/docs/guidelines%202009.pdf Accessed December 2, 2011. 3rd Edition ed: Ministry of Health Republic of Uganda.
15. (2008) National Guidelines for the Management of HIV and AIDS. Ministry of Health and Social Welfare, United Republic of Tanzania. www.fhi.org/NR/rdonlyres/../NatlGuideMgmtHIVTZfnl2008.pdf Accessed December 1, 2011. 3rd Edition ed: Ministry of Health and Social Welfare, United Republic of Tanzania.
16. (2010) National Guidelines for HIV & AIDS Care and Treatment. Ministry of Health and Social Welfare, Government of Lesotho. 3rd Edition ed: Ministry of Health and Social Welfare, Government of Lesotho.
17. (2010) National Guidelines for Antiretroviral Therapy. Ministry of Health and Social Services, Directorate of Special Programmes, Republic of Namibia. www.healthnet.org.na/documents/hiv_aids/National%20Guideline%20for%20Antiretroviral%20Therapy-%203rd%20Edition.pdf Accessed December 2, 2011. 3rd Edition ed: Ministry of Health and Social Services, Directorate of Special Programmes, Republic of Namibia.
18. (2006) Tratament Antiretroviral e Infeccoes Oportunistas Adulto e Adolescente. Ministerio de Saude, Mozambique. http://www.aidstar-one.com/sites/default/files/treatment_documents/hiv_treatment_guidelines_mozambique_2006.pdf. Accessed December 1, 2011. Ministerio de Saude, Mozambique.
19. (2008) Botswana National HIV/AIDS Treatment Guidelines: 2008 Version. Department of HIV/AIDS Prevention and Care, Botswana Ministry of Health. http://www.moh.gov.bw/templates/moh/File/BOTSWANA%20HIVAIDS%20TREATMENT%20%20GUIDELINES%20%28November%201%202008%29.pdf Accessed December 1, 2011.: Department of HIV/AIDS Prevention and Care, Botswana Ministry of Health.
20. Goujard C, Bernard N, Sohier N, Peyramond D, Lancon F, et al. (2003) Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr 34: 191-194.
21. Filmer D, Pritchett LH, (2001) Estimating wealth effects without expenditure data-or tears: an application to educational enrollments in states of India. Demography 38: 115-132.
22. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L, (1974) The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Science 19: 1-15.
23. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, (1998) The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 158: 1789-1795.
24. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.
25. Geng E, Muyindike W, Glidden D, Bwana M, Yiannoustos C,et al. Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART Period in Uganda: Understanding Engagement in Care in Resource-Limited Settings. Paper 1017.; 2011 February 27- March 3.; Boston, USA.
26. Zachariah R, Tayler-Smith K, Manzi M, Massaquoi M, Mwagomba B, et al. (2011) Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans R Soc Trop Med Hyg 105: 421-430.
27. Mulissa Z, Jerene D, Lindtjorn B, (2010) Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One 5: e13268.
28. Micek MA, Gimbel-Sherr K, Baptista AJ, Matediana E, Montoya P, et al. (2009) Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 52: 397-405.
29. Rosen S, Fox MP, (2011) Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8: e1001056.
30. Geng E, Bangsberg D, Musinguzi N, Emenyonu N, Bwana M, et al. (2009) Understanding Reasons for and Outcomes of Patients Lost to Follow-Up in Antiretroviral Threrapy Programs in Africa Through a Sampling-Based Approach. J Acquir Immune Defic Syndr.
31. Mshana GH, Wamoyi J, Busza J, Zaba B, Changalucha J, et al. (2006) Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: a qualitative study of early rural referrals to the national program. AIDS Patient Care STDS 20: 649-657.
32. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19: 658-665.
33. Wanyenze RK, Hahn JA, Liechty CA, Ragland K, Ronald A, et al. (2011) Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav 15: 751-760.
34. Pradier C, Bentz L, Spire B, Tourette-Turgis C, Morin M, et al. (2003) Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 4: 121-131.
35. Tuldra A, Fumaz CR, Ferrer MJ, Bayes R, Arno A, et al. (2000) Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 25: 221-228.
36. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, et al. (2011) A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 8: e1000422.
37. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100-1102.